  - Gladstone Institutes to set up new stem cell center
Gladstone Institutes in San Francisco said it has received a $5 million donation from the Roddenberry Foundation. The institute said the funding will go to the establishment of the new Roddenberry Center for Stem Cell Biology and Medicine. The center will research treatments with a focus on translating them into the clinical setting. San Francisco Chronicle (10/19)        | John Jantsch invites you to go local
As customers continue to rely on the Web to help them screen local businesses, local businesses must take steps to ensure that they pop to the top of online searches. Duct Tape Marketing's John Jantsch offers strategies for local marketing success in this free white paper from American Express OPEN, How to Win at the Local Marketing Game. Download your free copy now, exclusively for SmartBrief readers. |
 - Gene affects prostate, breast cancer growth differently
The androgen receptor gene promotes prostate cancer growth when it is activated, but it triggers breast cancer development when it is switched off, researchers say. Research reported in Oncogene found that the AR gene has the opposite effect on production of tumor suppressor protein PTEN in breast cancer cells as it does in prostate cancer cells. Yahoo!/Asian News International (10/17) - Antibody shows promise for Hendra virus protection
In a study of African green monkeys, those that were treated with the human antibody m102.4 survived after being injected with Hendra virus. After that test, researchers used the antibody in a woman and her daughter who had been exposed to the virus and found that the two were protected without any reported side effects. However, more studies are needed before the antibody could be used widely, researchers said. Google/Agence France-Presse (10/19) - Researchers to study use of cord blood for brain injury in children
The University of Texas Health Science Center at Houston and the Children's Memorial Hermann Hospital will work together on a study that will explore the potential of umbilical cord blood stem cells in treating traumatic brain injury in patients. The study will involve 10 children with moderate to severe traumatic brain injury whose cord blood has been stored with the Cord Blood Registry. KRIV-TV (Houston) (10/18)  | As eCommerce has grown to represent a significant percentage of retail sales and profits, merchants should consider payment strategies that can enhance their online services, open new markets and protect the bottom line. Download this free white paper to learn more. |
 - Abbott plans to split off pharmaceutical unit
Abbott Laboratories said it will spin off its drug division, through a tax-free distribution to shareholders. The firm seeks to bolster investor confidence in the remaining medical-product business, which will continue to use the Abbott name. "The pharma piece got so big and is so different that these two investments make sense separately, and both are of a critical mass and size that they have great sustainability going forward as independent companies," said Abbott Chairman and CEO Miles White. The Wall Street Journal (tiered subscription model)/Dow Jones Newswires (10/19), Reuters (10/19) - Vertex submits gene-targeting CF drug Kalydeco for FDA approval
Vertex Pharmaceuticals filed an FDA application seeking approval to promote Kalydeco, or ivacaftor, as treatment for cystic fibrosis in patients who carry a mutated G551D gene. The biotech company asked for fast-track review, which lasts six months. Kalydeco is a product of Vertex's 13-year alliance with the Cystic Fibrosis Foundation. Xconomy/Boston (10/19) - Amgen restructures to focus resources on late-stage drugs
Amgen said it is eliminating about 380 positions in research and development to focus resources on its late-stage drug pipeline. "It's very expensive to conduct clinical trials," said spokeswoman Mary Klem. "The patient population gets bigger at each phase. That's the crux of what is causing us to make these strategic changes." Los Angeles Times (10/20)  | FREE TRIAL – Thomson Reuters Cortellis™ Pipeline Intelligence
Discover new opportunities in drug development and licensing faster. Cortellis gives you an innovative way of finding and acting on drug pipelines, deals, patents, companies, breaking industry news, and conference coverage in one source, intuitively presented.
Click here to see if you qualify for a free trial! |
 | Industry Deals |  |  | |  | |  | | The Buzz(CORPORATE ANNOUNCEMENTS)
| |  | |  |
| Food & Agriculture | | | | | Industrial & Environmental | | | | - Advanced biofuels could reach market by 2013 or 2014, exec says
Advanced biofuels could become commercially available in the next several years, according to Stephan Tanda, a board member of the Netherlands-based group DSM. "We see refineries being built, particularly in the United States, in the next two years. So by 2014 or the end of 2013 we see a meaningful market with maybe about a dozen second-generation biorefineries," Tanda said. "In the beginning it will be small, but we see it growing at least as fast as first-generation fuels," said Tanda, adding that the market for yeast and enzymes for advanced biofuels could be worth as much as $3 billion to $5 billion a year within 10 years. Reuters (10/19) | News from BIO | | | | - BIOtechNOW
BIOtechNOW is the first in a number of new products from BIO intended to enhance our communications with the biotech community -- not only with our members, but with other stakeholders as well. This monthly e-newsletter, combined with its website, serves as our flagship in that effort. BIOtechNOW will offer original content that emphasizes the business needs of the industry; highlight BIO's advocacy efforts; and provide a portal to all BIO activities and events. Most importantly, it will spotlight for those outside the industry the value of biotechnology. Sign up for the monthly BIOtechNOW e-newsletter.
| SmartQuote | | | |  | A leader has the right to be beaten, but never the right to be surprised."
--Napoleon Bonaparte,
French military and political leader  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Wednesday, October 19, 2011
- Tuesday, October 18, 2011
- Monday, October 17, 2011
- Friday, October 14, 2011
- Thursday, October 13, 2011
| | | Lead Editor: Adam Gaub
Mailing Address:
SmartBrief, Inc.®, 1100 H ST NW, Suite 1000, Washington, DC 20005 | | | | | | © 1999-2011 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment